<DOC>
	<DOCNO>NCT00086125</DOCNO>
	<brief_summary>The purpose phase II study ass efficacy AP23573 patient specify relapsed refractory hematological malignancy .</brief_summary>
	<brief_title>Study AP23573 Patients With Relapsed Refractory Hematologic Malignancies ( 8669-024 ) ( COMPLETED )</brief_title>
	<detailed_description>The primary objective trial ass efficacy AP23573 patient specify relapsed refractory hematological malignancy evaluate response rate define individual malignancy category . Secondary objective include evaluate time disease progression , progression-free survival duration response ; evaluate pharmacokinetic pharmacodynamic characteristic AP23573 ; describe health-related quality life measurement ; explore safety tolerability AP23573 specify dose level . Protocol Outline : Open label , non-randomized parallel cohort five disease-specific cohort minimum 21 patient per cohort . Each patient receive fix dose AP23573 administer intravenously ( IV ) 30 minute daily five day ( QDx5 ) repeat every 2 week .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Metaplasia</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion Criteria ( Patients must meet follow criterion eligible participation trial ) : Male female patient â‰¥ 18 year age Patients must histologicallyconfirmed diagnosis relapsed refractory hematologic malignancy specify protocol Patients must ECOG performance status 0 2 Patients must adequate renal liver function demonstrate laboratory value perform within 5 day , inclusive , prior administration first dose AP23573 Patients must able understand give write informed consent Exclusion Criteria ( Patients meeting follow criterion ineligible participation study ) : Women pregnant lactate Patients may cytotoxic chemotherapy radiotherapy within 14 day prior study entry Patients may receive investigational anticancer agent study within 14 day prior first dose AP23573 Patients know suspected hypersensitivity drug formulate polysorbate 80 ( Tween ) excipient contain study drug formulation Patients know Grade 3 4 hypersensitivity macrolide antibiotic ( e.g. , clarithromycin , erythromycin , azithromycin ) Patients significant uncontrolled cardiovascular disease Patients know HIV infection Patients uncontrolled infection Patients receive immunosuppressive agent prescribed corticosteroid Patients prior therapy rapamycin , rapamycin analog tacrolimus Patients inadequate recovery prior surgical procedure patient undergone major surgical procedure within 14 day prior first dose AP23573 Patients lifethreatening illness organ system dysfunction , opinion Investigator , would either compromise patient 's safety interfere evaluation safety study drug Patients psychiatric disorder alter mental status would preclude understand informed consent process and/or completion necessary study Patients another primary malignancy within past three year ( except nonmelanoma skin cancer cervical carcinoma situ ) Patients inability , opinion Investigator , comply protocol requirement Drugs Other Treatments Excluded ( The follow drug treatment permit patient enrol study , either within two week prior first dose AP23573 , unless otherwise specify ) : Chemotherapeutic agent follow exception therapy nitrosoureas ( include generic ) give within six week prior first dose AP23573 Other antineoplastic agent Immunotherapy ( include vaccine ) biological response modifier therapy Systemic hormonal therapy exception specify protocol Herbal preparation related OTC preparation contain herbal ingredient ( e.g. , St John 's Wort ) Radiotherapy primary malignancy Any investigational agent course trial discuss Sponsor prior use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Relapsed refractory hematologic malignancy</keyword>
</DOC>